Combination therapy
US-9408847-B2 · Aug 9, 2016 · US
Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
US10010552B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10010552-B2 |
| Application number | US-201615003860-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 22, 2016 |
| Priority date | Jul 1, 2011 |
| Publication date | Jul 3, 2018 |
| Grant date | Jul 3, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer comprising administering to a human subject a therapeutically effective amount of a first agent that is a cyclin dependent kinase 4 or cyclin dependent kinase 6 (CDK4/6) inhibitor and a therapeutically effective amount of a second agent that is a PI3Kinase inhibitor, wherein the cancer is breast cancer or colon cancer. 2. The method of claim 1 wherein the first agent is Compound A described by Formula A: or a pharmaceutically acceptable salt thereof. 3. The method of claim 1 , wherein the second agent is Compound B1 described by Formula B1: or a pharmaceutically acceptable salt thereof. 4. The method of claim 1 , wherein the second agent is Compound B2 described by Formula B2: or a pharmaceutically acceptable salt thereof. 5. The method of claim 1 wherein the cancer is colon cancer. 6. The method of claim 1 wherein the cancer is breast cancer. 7. The method of claim 6 wherein the breast cancer is ER positive breast cancer. 8. The method of claim 6 wherein the breast cancer is Her2 positive breast cancer. 9. The method of claim 6 wherein the breast cancer is PI3K mutated breast cancer.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
specific for leukemia · CPC title
Antineoplastic agents · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10010552B2 cover?
- A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer.
- Who is the assignee on this patent?
- Kim Sunkyu, Doshi Shivang, Haas Kristy, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).